Merck Director Glocer to Retire in May 2027
Merck names Douglas M. Baker, Jr. as independent lead director effective January 1, 2027, succeeding Thomas H. Glocer in that role.
Updated on Nov. 18, 2026 in People

Merck announced that Thomas H. Glocer intends to retire from the Merck Board of Directors at the Annual Meeting of Shareholders in May 2027. The independent directors appointed Douglas M. Baker, Jr. as independent lead director, effective January 1, 2027.
Why it matters
The leadership transition sets up a change in the board's independent oversight role months before Glocer's planned departure. Baker's appointment gives the board continuity, as he has served on the Merck board since 2022.
Baker has served on the Merck Board of Directors since 2022 and will take the lead director post on January 1, 2027. The announcement does not specify a replacement director for Glocer's seat on the board.
The players
Merck
Merck is a global pharmaceutical company headquartered in Rahway, New Jersey, that develops medicines, vaccines and animal health products.
Douglas M. Baker, Jr.
Douglas M. Baker, Jr. is a former chairman and chief executive officer of Ecolab Inc. who has served on the Merck board since 2022 and is a trustee of Mayo Clinic.
Thomas H. Glocer
Thomas H. Glocer is a former chief executive of Thomson Reuters who has served on the Merck board and is retiring in May 2027.
The details
Merck's independent members of the board selected Douglas M. Baker, Jr., a former chairman and chief executive officer of Ecolab Inc. and a trustee of Mayo Clinic, to succeed Thomas H. Glocer as lead director. Glocer's retirement from the board is scheduled to take effect at the Annual Meeting of Shareholders in May 2027.
Timeline
January 1, 2027: Baker becomes independent lead director, succeeding Glocer in that role.
May 2027: Glocer retires from the Merck Board of Directors at the Annual Meeting of Shareholders.
Market Landscape
Planned, long-lead board transitions like this one are common at large U.S. drugmakers, where independent lead directors typically provide oversight as chief executives change. The Merck announcement gives advance notice of a transition set to play out over roughly a year and a half.
For Merck shareholders, the transition signals continuity in board oversight, with an experienced director taking the lead role. The change has no direct effect on products, pricing or availability for consumers or patients.
The takeaway
Long-lead board transitions give shareholders time to evaluate leadership continuity before a change takes effect. Watching who fills vacated seats can reveal how a company plans to manage its oversight over the coming years.
What happens next
Glocer is scheduled to retire from the Merck board at the Annual Meeting of Shareholders in May 2027, and Baker's lead director role begins January 1, 2027.
Further reading
For more on corporate leadership changes, see People coverage on Wisevoter.
Source note: This article includes information reported by Firstwordpharma.






